Fundoplication Clinical Trial
— HEURISTICOfficial title:
Hernia Reduction Prior to Scheduled TIF Completion- The HEURISTIC Study
Verified date | October 2020 |
Source | EndoGastric Solutions |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Hernia Reduction Prior to Scheduled TIF Completion using EsophyX ZR transoral device
Status | Terminated |
Enrollment | 14 |
Est. completion date | October 26, 2020 |
Est. primary completion date | April 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 72 Years |
Eligibility | Inclusion Criteria: 1. Age 18-72 years 2. Dependent upon daily PPIs for > 6 months. Daily use is defined as a double dose, or full dose or half dose taken daily for more than 80% of the total number of days during the proceeding evaluation period 3. Troublesome symptoms, specifically heartburn or regurgitation, while on optimized dose of PPI's Troublesome heartburn or regurgitation symptoms are those which occur a minimum of 2 days a week and are mild to severe in severity 4. Abnormal ambulatory (Bravo) pH study after off PPI therapy for 7 days, i.e. > 5.3% of the time with pH < 4 in a 48-hour monitoring period 5. Normal or near normal esophageal motility (by Upper GI/ esophagram or manometry as required) 6. Pre-enrollment Hiatal Hernia (axial height and transverse dimension) from > 2 cm up to 4 cm inclusive. 7. Patient willing to cooperate with post-operative dietary recommendations and assessment tests at the requisite follow-up visits 8. Signed informed consent Exclusion Criteria 1. BMI > 35 2. Hiatal hernia = 2 and > 4 cm 3. Esophagitis Los Angeles grade C or D 4. Esophageal ulcer 5. Esophageal stricture 6. Long-segment Barretts esophagus (Prague: C > 1, M > 3) 7. Esophageal motility disorder 8. Pregnancy or plans for pregnancy in the next 12 months (in females) 9. Immunosuppression 10. ASA > 2 11. Portal hypertension and/or varices 12. History of previous resective gastric or esophageal surgery, cervical spine fusion, Zenker's diverticulum, esophageal epiphrenic diverticulum, achalasia, scleroderma or dermatomyositis, eosinophilic esophagitis, or cirrhosis 13. Active gastro-duodenal ulcer disease 14. Gastric outlet obstruction or stenosis 15. Severe gastroparesis or delayed gastric emptying confirmed by solid-phase gastric emptying study if patient complains of postprandial satiety during assessment 16. Coagulation disorders 17. Atypical symptoms including gas bloat and dysphagia. 18. Any other presenting condition that in the opinion of the investigator would not make participation in this study in the patient's best interest. Post Enrollment Exclusion - 1. Inability to repair Hiatal hernia with at least 2cm of intra-abdominal esophagus length. |
Country | Name | City | State |
---|---|---|---|
United States | Elkhart General Hospital | Elkhart | Indiana |
United States | Aspirus Iron River Hospital | Iron River | Michigan |
United States | Northern Nevada Medical Center | Sparks | Nevada |
Lead Sponsor | Collaborator |
---|---|
EndoGastric Solutions |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | pH Study | Number of Participants with Normalization of Esophageal Acid Exposure. Normalization in esophageal acid exposure is defined by = 5.3% of total time pH < 4 in | 48 hour monitoring period | |
Secondary | Number of Participants With a Change in Troublesome Symptoms From Baseline | Per Montreal Consensus definition, troublesome symptoms are mild symptoms occurring two (2) or more days per week, or moderate/severe symptoms occurring more than 1 day per week | 6 months | |
Secondary | Number of Participants With a Change in PPI Consumption From Baseline to 6 Months | from daily use to occasional use or none at all. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05068089 -
Health, Economic Analysis and Clinical Aspects of Patients With Neurological Disabilities in Enteral Nutrition With Dedicated Formula. The Role of Nissen's Fundoplication in the Management of Gastroesophageal Reflux
|
||
Terminated |
NCT02708303 -
Mayo Clinic Foregut Surgery Report Card Questionnaire
|
||
Completed |
NCT03536169 -
Utilization of Anti-reflux Treatment and Course of Illness Leading to Reoperation
|
||
Completed |
NCT01307982 -
Comparative Anti-Reflux Procedures in Neurologically Impaired Children
|
N/A |